Efficacy and Safety of Intravenous + Oral Vs. Oral Amiodarone in Preventing Recurrence After Catheter Ablation in Patients with Persistent Atrial Fibrillation
The Efficacy and Safety of Intravenous + Oral Vs. Oral Amiodarone in Preventing Recurrence After Catheter Ablation in Patients with Persistent Atrial Fibrillation
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Shaohui Wu
- Phone Number: 15821960839
- Email: wushaohui18@163.com
Study Locations
-
-
Xuhui
-
Shanghai, Xuhui, China
- Shanghai Chest Hospital
-
Contact:
- Shaohui Wu
- Phone Number: 15821960839
- Email: wushaohui18@163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants aged ≥18 years;
- First-time catheter ablation for persistent atrial fibrillation (defined as any - previous episode lasting ≥7 days);
- Symptomatic atrial fibrillation patients who have failed or are intolerant to at least one class I or III antiarrhythmic drug;
- Participants who are able to understand the purpose of the study, voluntarily agree to participate, and provide written informed consent.
Exclusion Criteria:
- Those unwilling or unsuitable to restart or continue antiarrhythmic drug therapy;
- Life expectancy < 12 months;
- Severe liver or kidney dysfunction;
- Allergy to amiodarone components;
- Pregnant or breastfeeding women;
- Contraindications to amiodarone (e.g., blood pressure < 90/60 mmHg; bradycardia < 55 bpm, second- or third-degree AV block, or sick sinus syndrome);
- Thyroid disorders, such as hyperthyroidism or hypothyroidism.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Experimental group (Intravenous + Oral Amiodarone)
Within 24 hours post-operation, patients will receive an intravenous amiodarone loading dose of 300 mg QD along with oral amiodarone 200 mg BID.
This regimen will be continued for 3 days, after which intravenous amiodarone will be discontinued, and oral amiodarone 200 mg BID will be continued for 3 months.
|
Administer 300 mg of intravenous amiodarone as a loading dose once daily (QD) and 200 mg of oral amiodarone twice daily (BID) within 24 hours postoperatively, and continue for 3 consecutive days.
|
|
Placebo Comparator: Control group (Oral Amiodarone only)
Postoperatively, instead of administering intravenous amiodarone, sodium chloride injection was used as a placebo, and oral amiodarone 200 mg BID was directly given for 3 months.
|
Sodium chloride injection as a placebo in an amount equivalent to amiodarone injection.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Recurrence of atrial arrhythmia lasting more than 30 seconds.
Time Frame: At least 12 months of follow-up, beyond the initial 3 month blanking period
|
After a single ablation procedure, with at least 12 months of follow-up, any atrial arrhythmia recorded for more than 30 seconds - including atrial fibrillation (AF), atrial tachycardia (AT), or atrial flutter (AFL) - occurring beyond the initial 3-month blanking period.
|
At least 12 months of follow-up, beyond the initial 3 month blanking period
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Recurrence of atrial fibrillation (AF) lasting more than 30 seconds.
Time Frame: At least 12 months of follow-up, beyond the initial 3 month blanking period
|
After a single ablation procedure, with at least 12 months of follow-up, any atrial arrhythmia recorded for more than 30 seconds - including atrial fibrillation (AF) - occurring beyond the initial 3-month blanking period.
|
At least 12 months of follow-up, beyond the initial 3 month blanking period
|
|
Recurrence of atrial arrhythmias during the 3-month blanking period after atrial fibrillation (AF) surgery.
Time Frame: During the 3-month blanking period after atrial fibrillation (AF) surgery
|
Recurrence of atrial arrhythmias during the 3-month blanking period after atrial fibrillation (AF) surgery.
|
During the 3-month blanking period after atrial fibrillation (AF) surgery
|
|
hospital readmission for re-ablation, electrical cardioversion and adverse drug events (ADEs)
Time Frame: At least 12 months of follow-up
|
During the follow-up period, hospital readmission for re-ablation, electrical cardioversion and adverse drug events (ADEs), including bleeding, liver dysfunction, renal dysfunction, skin sensitivity, gastrointestinal adverse reactions, bradyarrhythmia (<55 bpm), ischemic stroke, and hyperthyroidism, etc.
|
At least 12 months of follow-up
|
|
Quality of life assessment using AFEQT
Time Frame: At least 12 months of follow-up
|
Assessment of quality of life using the AFEQT (Atrial Fibrillation Effect on Quality of Life Questionnaire) during at least 12 months of follow-up.
|
At least 12 months of follow-up
|
|
Serum drug concentrations of amiodarone and its metabolite desethylamiodarone.
Time Frame: At 1 month and 3 months after surgery.
|
Serum drug concentrations of amiodarone and its metabolite desethylamiodarone at 1 month and 3 months after surgery.
|
At 1 month and 3 months after surgery.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Pathologic Processes
- Heart Diseases
- Disease Attributes
- Arrhythmias, Cardiac
- Recurrence
- Atrial Fibrillation
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Anti-Arrhythmia Agents
- Sodium Channel Blockers
- Membrane Transport Modulators
- Cytochrome P-450 Enzyme Inhibitors
- Vasodilator Agents
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 CYP2D6 Inhibitors
- Potassium Channel Blockers
- Cytochrome P-450 CYP1A2 Inhibitors
- Cytochrome P-450 CYP2C9 Inhibitors
- Amiodarone
Other Study ID Numbers
Other Study ID Numbers
- ITAD-PAF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.